Treatment for Pyelonephritis in Women
For outpatient management of uncomplicated pyelonephritis in non-pregnant women, use oral ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days when local fluoroquinolone resistance is <10%; if resistance exceeds 10%, administer one dose of IV ceftriaxone 1-2 g before starting oral therapy 1.
Non-Pregnant Women
Outpatient Treatment (Mild-Moderate Disease)
First-line oral regimens:
- Ciprofloxacin 500-750 mg twice daily for 7 days 1
- Levofloxacin 750 mg once daily for 5 days 1
- Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days (only if pathogen known to be susceptible) 1
Critical caveat: Fluoroquinolones should only be used empirically when local resistance rates are <10% 1, 2. If your community has >10% fluoroquinolone resistance, you must give one initial dose of a long-acting parenteral antibiotic (ceftriaxone 1-2 g IV or aminoglycoside) before starting oral therapy 1, 2.
Oral cephalosporins (cefpodoxime 200 mg twice daily for 10 days or ceftibuten 400 mg daily for 10 days) are acceptable alternatives but achieve lower blood concentrations than IV formulations, so consider an initial IV ceftriaxone dose 1.
Avoid these agents: Nitrofurantoin, oral fosfomycin, and pivmecillinam lack sufficient efficacy data for pyelonephritis and should not be used 1.
Inpatient Treatment (Severe Disease or Unable to Tolerate Oral)
Initial IV regimens:
- Ciprofloxacin 400 mg twice daily 1
- Levofloxacin 750 mg once daily 1
- Ceftriaxone 1-2 g once daily 1
- Cefepime 1-2 g twice daily 1
- Piperacillin-tazobactam 2.5-4.5 g three times daily 1
- Gentamicin 5 mg/kg once daily (with or without ampicillin) 1
- Amikacin 15 mg/kg once daily 1
Reserve carbapenems and novel agents (meropenem, ceftolozane-tazobactam, ceftazidime-avibactam) exclusively for patients with early culture results showing multidrug-resistant organisms 1.
Essential Diagnostic Steps
Always obtain:
- Urine culture and antimicrobial susceptibility testing before starting antibiotics 1
- Urinalysis (white cells, red cells, nitrite) 1
Imaging indications:
- Ultrasound if history of kidney stones, renal dysfunction, or high urine pH 1
- CT scan with contrast if patient remains febrile after 72 hours or clinical deterioration occurs 1
- Prompt imaging is crucial to differentiate uncomplicated from obstructive pyelonephritis, which can rapidly progress to urosepsis 1
Pregnant Women
Pregnant women with pyelonephritis require hospitalization and initial IV therapy due to significantly elevated risk of severe complications 3, 4.
Initial IV regimens (pregnancy-safe):
- Ceftriaxone 1-2 g once daily 1
- Cefepime 1-2 g twice daily 1
- Piperacillin-tazobactam 2.5-4.5 g three times daily 1
- Gentamicin 5 mg/kg once daily (with or without ampicillin) 1
Avoid fluoroquinolones in pregnancy - they are contraindicated 1.
Imaging in pregnancy: Use ultrasound or MRI preferentially to avoid radiation exposure to the fetus 1.
Treatment Duration and De-escalation
- Fluoroquinolones: 5-7 days 1
- Trimethoprim-sulfamethoxazole: 14 days 1
- Oral cephalosporins: 10 days 1
- Beta-lactams: 10-14 days 2
Tailor therapy based on culture results as soon as susceptibility data are available 1. Switch from IV to oral therapy when clinically improved and able to tolerate oral intake.
Common Pitfalls to Avoid
Using fluoroquinolones blindly: Check your local antibiogram - if E. coli resistance exceeds 10%, you need initial parenteral therapy 1, 2
Treating without cultures: Always obtain urine culture before antibiotics in pyelonephritis 1
Missing obstruction: Failure to image promptly can miss obstructive pyelonephritis requiring urgent urological decompression 1
Outpatient treatment in pregnancy: Pregnant women must be hospitalized 3, 4
Using inappropriate oral agents: Nitrofurantoin and fosfomycin are ineffective for pyelonephritis despite working for cystitis 1
Delayed imaging in non-responders: If fever persists beyond 72 hours, obtain CT imaging immediately and consider alternative diagnoses or complications 1
Resistance Considerations
The 2024 EAU guidelines emphasize that local resistance patterns must guide empirical therapy 1. Fluoroquinolone resistance is rising globally, with some European hospitals reporting >18% resistance rates 5. When resistance is high, the initial parenteral dose strategy becomes essential to ensure adequate coverage while awaiting susceptibility results.